Recipharm expands Swedish facility; FDA warns Chinese OTC maker; DSM, Indoco ink pact;

> Sweden's Recipharm will expand capacity of its analytical services and stability studies at its facility in Solna, Sweden. Release

> The FDA has warned Shanghai Huhui Daily Use Chemical Products that its products may be refused entry into the U.S. until it fixes a host of problems inspectors found at its manufacturing plant in Shanghai. Warning Letter

> India-based packaging company ACG Worldwide is plunking down about $71 million in the phased construction of a new manufacturing plant at Pithampur, Indore, India. Item

> DSM Pharmaceuticals has struck a deal with Indian API maker Indoco Remedies to sell 8 of its active pharmaceutical ingredients. Item

And Finally... With the patent cliff ending for branded drugmakers, the fiscal precipice now looms for generics makers. Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.